In our study, 47.6% of patients were classified as having intermediate-to-high risk of clinically significant liver fibrosis (≥F2) as per the FIB-4 index, 48.2 and 65.6% patients reported elevated plasma aminotransferase levels (AST > 40 U/L and/or ALT >40 U/L, respectively). The gene discussed is GPT; the disease is Hepatic fibrosis.